CYTEK BIOSCIENCES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.805 USD | -2.60% |
|
-5.67% | -36.18% |
| Mar. 20 | Cytek Biosciences Insider Sold Shares Worth $269,600, According to a Recent SEC Filing | MT |
| Mar. 19 | Cytek Biosciences Appoints William McCombe as CFO, Reaffirms 2024 Guidance | MT |
Financials (USD)
| Sales 2024 * | 208M | Sales 2025 * | 247M | Capitalization | 780M |
|---|---|---|---|---|---|
| Net income 2024 * | -7M | Net income 2025 * | 7M | EV / Sales 2024 * | 2.69 x |
| Net cash position 2024 * | 221M | Net cash position 2025 * | 235M | EV / Sales 2025 * | 2.21 x |
| P/E ratio 2024 * |
-166
x | P/E ratio 2025 * |
67.7
x | Employees | 676 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.29% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cytek Biosciences, Inc.
More recommendations
More press releases
| 1 day | +0.68% | ||
| 1 week | -5.40% | ||
| Current month | -11.18% | ||
| 1 month | -12.35% | ||
| 3 months | -28.28% | ||
| 6 months | +23.14% | ||
| Current year | -34.65% |
1 week
5.71
6.27
1 month
5.717.02
Current year
5.719.33
1 year
3.8012.31
3 years
3.8028.70
5 years
3.8028.70
10 years
3.8028.70
| Managers | Title | Age | Since |
|---|---|---|---|
Ming Yan
FOU | Founder | 61 | 14-11-30 |
Wen Bin Jiang
FOU | Founder | 60 | 14-11-30 |
Chris Williams
COO | Chief Operating Officer | 55 | 22-10-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donnie Hardison
BRD | Director/Board Member | 74 | 22-05-31 |
Deborah Neff
BRD | Director/Board Member | 71 | - |
Jack Ball
BRD | Director/Board Member | 77 | 18-11-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.19% | 27 M€ | -7.00% | - | |
| 0.11% | 0 M€ | 0.00% | - | |
| 0.11% | 45 M€ | -2.89% | ||
| 0.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 5.82 | -2.35% | 158 526 |
| 24-04-18 | 5.96 | +0.68% | 674,717 |
| 24-04-17 | 5.92 | -0.84% | 709,569 |
| 24-04-16 | 5.97 | -0.83% | 2,270,582 |
| 24-04-15 | 6.02 | -2.43% | 1,394,395 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
5.96
USD
Average target price
10
USD
Spread / Average Target
+67.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.65% | 780M | |
| +2.02% | 207B | |
| +2.17% | 175B | |
| +10.45% | 132B | |
| +16.62% | 99.1B | |
| -4.37% | 60.89B | |
| +13.38% | 52.04B | |
| -6.33% | 45.48B | |
| -4.74% | 38.81B | |
| +9.89% | 38.77B |
- Stock Market
- Equities
- CTKB Stock
